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Background: Opioids can produce life-threatening respiratory depression. This study tested whether subanaesthetic
doses of esketamine stimulate breathing in an established human model of opioid-induced respiratory depression.
Methods: In a study with a randomised, double blind, placebo controlled, crossover design, 12 healthy, young volunteers
of either sex received a dose escalating infusion of esketamine (cumulative dose 40 mg infused in 1 h) on top of
remifentanil-induced respiratory depression. A population pharmacokinetic-pharmacodynamic analysis was performed
with sites of drug action at baseline ventilation, ventilatory CO2-chemosensitivity, or both.
Results: Remifentanil reduced isohypercapnic ventilation (end-tidal PCO2 6.5 kPa) by approximately 40% (from 20 to 12
litre min1) in esketamine and placebo arms of the study, through an effect on baseline ventilation and ventilatory CO2
sensitivity. The reduction in ventilation was related to a remifentanil effect on ventilatory CO2 sensitivity (~39%) and on
baseline ventilation (~61%). Esketamine increased breathing through an exclusive stimulatory effect on ventilatory CO2
sensitivity. The remifentanil concentration that reduced ventilatory CO2 sensitivity by 50% (C50) was doubled at an
esketamine concentration of 127 (84-191) ng ml1 [median (interquartile range)]; the esketamine effect was rapid and
driven by plasma pharmacokinetics. Placebo had no systematic effect on opioid-induced respiratory depression.
Conclusions: Esketamine effectively countered remifentanil-induced respiratory depression, an effect that was attrib-
uted to an increase in remifentanil-reduced ventilatory CO2 chemosensitivity.
Keywords: esketamine; opioid; respiratory compromise; respiratory depression; reversalThe observation that opioids produce life-threatening respi-
ratory depression is not new. The first reported death from i.v.
morphine dates from the 1850s when Englishman Alexander
Wood injected his wife with morphine just after the intro-
duction of the hollow needle.1 Public awareness of the
potentially life-threatening adverse effects of opioids is new,
however, and is related to the recent escalation of prescribed
opioid consumption and prescribed opioid deaths in the USA
and other western countries.2e4 The combination of opioid
misuse and cardiorespiratory depression in particular isEditorial decision: February 17, 2018; Accepted: February 17, 2018
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For Permissions, please email: permissions@elsevier.compotentially lethal. While it is well established that the increase
in deaths occurs in patients that consume opioids in the
community (i.e. opioids prescribed for treatment of chronic
pain), opioid-induced respiratory depression (OIRD) is an
equally relevant problem for patients treated with potent
opioids in the acute or hospital setting.5e7
In recent years, various pharmacological interventions
have been proposed to offset OIRD, most of which are respi-
ratory stimulants that do not interact with the opioid receptor
system, so that opioid analgesia is not compromised.8 Whilerved.
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Editor’s key points
 The authors tested whether subanaesthetic doses of
esketamine (S(+) enantiomer of ketamine) stimulate
breathing during opioid-induced respiratory depres-
sion in healthy human volunteers.
 Pharmacokineticepharmacodynamic analyses were
undertaken to establish whether esketamine affected
baseline ventilation and/or ventilatory CO2-
chemosensitivity.
 Esketamine dose-dependently increased breathing
only during opioid induced ventilatory depression,
exclusively through a stimulatory effect on ventilatory
CO2 sensitivity.
 Low-dose ketamine may be an effective strategy to
reduce ventilatory depression after opioid
administration.
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doxapram), others are experimental drugs that require further
research (ampakines, 5HT-agonsists, methylxanthines, drugs
acting at background potassium channels of type 1 carotid
body cells).8e11 In the current study, we assess whether the
commonly used anaesthetic esketamine is able to reverse, at
subanaesthetic dose, (part of) the respiratory depression
induced by a potent opioid. Recent animal and human data
suggest that ketamine is a respiratory stimulant and conse-
quently may possibly offset OIRD.12e15 Ketamine is different
from other respiratory stimulants in that it has inherent
analgesic properties. Consequently, if ketamine is able to
reverse OIRD, it may also reduce opioid consumption.16
We performed two studies. The first was a double blind,
randomised, placebo-controlled, crossover trial designed as a
proof-of-concept study to investigate the effect of dose-
escalating infusions of esketamine (four steps with a cumu-
lative dose of 40 mg per 70 kg given in 1 h) on opioid-induced
respiratory depression under isohypercapnic conditions. We
measured esketamine plasma concentrations and minute
ventilation and performed a population pharmacokinetic
(PK)epharmacodynamic (PD) analysis. We hypothesise that
(low-dose) esketamine will effectively reduce remifentanil-
induced respiratory depression. To further understand esket-
amine’s effect on ventilation, we next examined, in an
observational study, whether esketamine is a respiratory
stimulant when respiration is not depressed by an opioid.Methods
Ethics and subjects
This single-centre, double blind, placebo-controlled, crossover
study protocol was performed from November 2016 to July
2017 at the Anesthesia and Pain Research Unit of the Depart-
ment of Anesthesiology at the Leiden University Medical
Center. The local Institution Review Board (Commissie Medi-
sche Ethiek, Leiden, The Netherlands) and the Central Com-
mittee on Research involving Human Subjects (CCMO, The
Hague, The Netherlands) approved the study protocol. Written
informed consent was obtained from all participants before
enrolment. All study procedures were conducted according to
good clinical practice guidelines and adhered to the tenets of
the Declaration of Helsinki. Participants were recruited byflyers posted on the campus of the university. The study was
registered in the Dutch trial register (identifier 6248).
Healthy volunteers, aged 18e40 yr, with a body mass index
<30 kg m2 and able to read and understand the subject in-
formation form were recruited. Exclusion criteria were: a
medical history of medical or psychiatric disease; any allergy
to food or medication; alcohol abuse (i.e. >21 units per week);
smoking; pregnancy or lactation; participation in an investi-
gational drug trial in the 3 months before the current study;
illicit drug use in the 30 days before the current study; or a
positive urine dipstick on the screening or study days. The
dipstick (Alere Toxicology Plc, Oxfordshire, UK) tests for
cocaine, amphetamine, cannabinoids, phencyclidine, metha-
done, benzodiazepine, tricyclic antidepressants, and barbitu-
rates. Subjects were asked not to eat and drink for 8 h before
dosing, not to take caffeinated drinks, chocolate drinks or
alcohol for 24 h before dosing and to refrain from grapefruit
(juice) for 7 days before the first study visit and thereafter for
the duration of the study.Study design
Subjects visited the research unit on three separate occasions,
at least 1 week apart. On visits 1 and 2, the effect of esketamine
(Ketanest-S, Pfizer, The Netherlands) on opioid-induced res-
piratory depression was tested using a double-blind placebo-
controlled, crossover design. Subjects were randomised to
receive either esketamine or placebo (normal saline) on top of
remifentanil (GlaxoSmithKline BV, The Netherlands) induced
respiratory depression. On the third occasion, the effect of just
esketamine on ventilation was studied (i.e. without remi-
fentanil). Subjects received two i.v. access lines (one for
esketamine or placebo and the other for remifentanil infusion)
and a 22 G cannula in the left or right radial artery for blood
sampling. During the study day, subjects were monitored by
ECG, oxygen saturation via a finger probe and blood pressure
through the arterial line.Drug administration
Remifentanil was administered i.v. by target-controlled infu-
sion on visits 1 and 2 (Supplementary Fig. S1). The remifentanil
target controlled infusion system makes use of Minto and
colleagues’17 pharmacokinetic data set. The target concen-
tration was started at 0.5 ng ml1 and step-wise increased to a
specific end-point (i.e. a decrease in ventilation by 40e50% of
baseline value). Titration to effect was performedwith steps in
target remifentanil concentration of 0.1e0.5 ng ml1. After
ventilation had reached a steady state for at least 10 min, the
esketamine/placebo infusion began. Esketamine or placebo
were administered by i.v. dose-escalating infusions over 60
min: 0e15 min 4 mg (step 1), 15e30 min 8 mg (step 2), 30e45
min 12 mg (step 3) and 45e60 min 16 mg (step 4); all doses are
per 70 kg. After the 1 h esketamine infusion, the remifentanil
infusion continued for another 15 min (see also Fig. 1). In case
ventilation reached baseline values during steps 1, 2, or 3, a
next step increase in ketamine was not performed and the
esketamine infusion was ended at the end of the 15 min
infusion of that particular step.Ventilation measurements
On all three occasions, ventilation was measured on a breath-
to-breath basis using the Dynamic End-Tidal Forcing
Fig 1. (A) Population averages of the plasma esketamine concentration of visits 1 or 2 (blue symbols) and visit 3 (red symbols). (B) The effect
of esketamine on remifentanil-induced respiratory depression. To guide the eye, the placebo data are plotted on top of the esketamine
data (orange broken line). (C) The effect of placebo on remifentanil-induced respiratory depression. To guide the eye, the remifentanil data
are plotted on top of the placebo data (blue broken line). (D) The results of the observational trial of visit 3. All data are mean with 95%
confidence interval (CI). The black lines are the esketamine infusion scheme, the broken black lines the remifentanil infusions. The dotted
red lines in (D) reflect the baseline values of ventilation and end-tidal PCO2.
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to a pneumotachograph (#4813; Hans Rudolph Inc., Shawnee,
KS, USA). The inhaled gas mixture came from three mass flow
controllers (for O2, N2, and CO2; Bronkhorst High-Tech BV, The
Netherlands) thatwere controlled using custom-made software
(RESREG/ACQ, Leiden University, Leiden, Netherlands). On
visits 1 and 2 the inspired CO2 concentration was manipulated
to elevate and clamp the end-tidal PCO2 to a level that caused
an increase in mean [standard deviation (SD)] ventilation to 20
(2) litre min1, while end-tidal PO2 was strictly maintained at a
normoxic value (14.5 kPa). When ventilation reached a steadystate under these isohypercapnic and iso-oxic conditions the
remifentanil infusion was started followed by the esketamine
or placebo infusion. After the remifentanil infusion had ended,
ventilation measurements at isohypercapnic and iso-oxic
conditions continued for another 15 min.
On the third visit, ventilation was measured under poiki-
locapnic conditions (i.e. without CO2 clamping). The esket-
amine administration was similar to the infusion scheme of
visit 1 or 2, however, without administration of remifentanil.
Minute ventilation and end-tidal PCO2 averages were calcu-
lated and used in the data analysis.
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At the end of drug infusion, sedation and drug high were
measured on an 11-point verbal rating scale (VRS) ranging
from 0 (no effect) to 10 (maximum effect).Blood sampling
To quantify the esketamine concentrations, arterial blood
samples were collected in 6-ml heparin tubes. Blood samples
were obtained at baseline (before any esketamine infusion)
and t¼1, 4, 10, 15, 17, 25, 30, 32, 40, 45, 47, 55, 60, 62, 65, 70, 80,
90, and 120 min after the start of esketamine infusion
(Supplementary Fig. S1). Within 30 min after collection, blood
samples were centrifuged at 450 g for 15 min at 4C; 2e3 ml
plasma was separated and stored at e80C until analysis.
Esketamine measurements were performed at the University
of Groningen on a TSQ Quantum™ Access MAX Triple Quad-
rupole mass spectrometer (Thermo Fisher Scientific, Wal-
tham,MA, USA) using a Vanquish autosampler (Thermo Fisher
Scientific) and injections of 5 ml. The linear range of the assay
was 2.5e2000 ng ml1; the lower limit of quantitation was 0.5
ng ml1 for esketamine. The data were analysed using Xcali-
bur software (Thermo Fisher Scientific).Randomisation and allocation
Randomisation was performed using a computer-generated
randomisation list by an individual not involved in the study
after all relevant parties (institutional and national review
boards, pharmacy, departmental research board) approved
the study protocol. The randomisation list was used by the
pharmacy to prepare the study medication. The researchers
notified the pharmacy of the subject number on the day before
the study. Esketamine or saline were delivered to the labora-
tory on the morning of the study in syringes labelled with
subject and visit numbers (1 or 2) only. The research team
prepared all other medication. The team remained blinded to
treatment until the data acquisition was completed.Data analysis
A population PKePD model was constructed in which the
esketamine’s PK was linked to the remifentanil potency
parameter (i.e. C50 or the concentration remifentanil that
reduced ventilation by 50%). The population analyses were
performed in NONMEM version 7.4.1 (software for nonlinear
mixed effects modelling; Icon plc, Gaithersburg, MD, USA).
Model selection was based on theminimum objective function
value (c2 test), standard error of estimates (SEE) and goodness
of fit plots. For both PK and PD analysis, the model parameters
were assumed to be log-normally distributed across the pop-
ulation. Residual error was assumed to have both an additive
and a relative error for concentrations and only an additive
error for ventilation. All values in the PKePD analysis are
median (SEE ¼ standard error of the estimate); P-values < 0.01
were considered significant.
The analyses were performed simultaneously on remi-
fentanil/esketamine and remifentanil/placebo data in multi-
ple steps (with estimation of interoccasion variability for the
remifentanil model parameters). (i) First the esketamine PK
data were analysed using a three-compartment model.
Initially, the structural parameters of Sigtermans and col-
leagues19 were implemented, after which we searched for
systematic deviations from that model. (ii) For remifentanil, itwas assumed that the target-controlled infusion values
correctly reflect the plasma concentrations. (iii) For both
esketamine (E) and remifentanil (R), a possible hysteresis be-
tween plasma concentration and effect was modelled by
assuming effect compartments with blood-effect-site equili-
bration half-times, t½E and t½R, respectively. (iv) Next, the
population PD model parameters were determined with fixed
empirical Bayesian individual drug PK model parameters.
Inspired minute ventilation ( _VE) was modelled as
20:
_VE ¼ _VBLN þ S ðPTCO2  PTBCO2Þ (1)
where _VBLN is baseline ventilation obtained without any
inspired CO2, S the ventilatory carbon dioxide sensitivity,
PTCO2 the CO2 concentration at the site of chemoreception
(and instantaneously related to _VE) and PTBCO2 the baseline
value of PTCO2. In our isohypercapnic experiments, PTCO2 was
assumed to be constant over time, hence (PTCO2ePTBCO2) is a
constant. We next assume that remifentanil depresses venti-












_VE ¼ ð1 lÞ  Y1þ l Y2 (4)
where CREM is the remifentanil effect-site concentration and
C501 the concentration remifentanil that _VBLN by 50%, C502 the
concentration remifentanil that reduces S by 50%, G1 and G2
shape factors and l a constant. Since the effect of remifentanil
on S and _VBLN may effectively occur at separate sites in the
brainstem, we postulated two distinct equilibration half-
times, t½R1 and t½R2.
We assume that esketamine may increase C501 or C502 as
follows:


















where C501(0) and C502(0) are the respective remifentanil C501
and C502 values when the esketamine effect-site concentra-
tion is zero, CKET the esketamine effect-site concentration, C
K
D1
and CKD2 the esketamine effect-site concentrations causing a
doubling of C501 and C502, respectively, and Q a shape factor.
The effect of placebo on remifentanil-induced respiratory
depression was modelled as follows:









where CP is the assumed esketamine concentration during
placebo treatment.
Amixture analysiswasperformedonCKD2with four possible
response subgroups. An individual can be a ketamine
responder or non-responder, and a placebo responder or non-
responder, giving four possibilities. The mixture analysis was
done in NONMEM, by specifying: (i) the probability of being a
ketamine responder and the probability of being a placebo
responder; and (ii) the CKD2 values of the four subgroups: an
Esketamine counters opioid respiratory depression - 1121estimable parameter for ketamine, an estimable parameter for
placebo, and a fixed potency of zero (corresponding to a CKD2 of
infinity) for the (ketamine and placebo) non-responders. The
probability parameters are estimated by NONMEM by mini-
mising the objective function as usual. In addition, NONMEM
estimates to which of the four subgroups the individuals are
the most likely to belong, on the basis of which the ketamine/
placebo responder/non-responder status of the subjects were
assessed and counted. The choice of CKD2 for mixture analysis
was based on the objective functions of the variousmodels that
were tested. These models included: (i) a model in which
remifentanil had an effect at a single component Y vs an effect
at Y1 and Y2; (ii) amodel with an esketamine effect on CKD1 and
CKD2withC
K
D1 ¼ CKD2 vs an effect at just CKD2; (iii) amodelwith an






D2 vs an effect at
just CKD2; (iv) amodel inwhichQwas not fixed vsQfixed to 1; (v)
a model in which esketamine was compared with placebo
without any mixture analysis vs the mixture analysis as
described above; and (vi) a model in which placebo and esket-
amine data were grouped with a mixture analysis with two
possible groups (responders and non-responders) vs a model
with mixture analysis with four groups as described above.
We calculated normalised prediction discrepancies (NPD;
by NONMEM) as a visual predictive check of the final esket-
amine model.21,22 In brief, 300 Monte Carlo simulations (of the
final model output based on the fixed and distributions of the
random effects) were performed and the number of times an
observation is greater than the model prediction is counted.
The NPD are the counts divided by 300, transformed via the
inverse normal distribution. Under the null hypothesis that
the model is correct, the NPD should have a normal distribu-
tion. It was checked by visual inspection that the NPD vs time
showed no trends, heteroscedasticity, or both.Results
Sixteen subjects of either sex were enrolled in the study. Two
subjects ended their participation during screening because of
facemask discomfort, two others because of esketamine-
induced psychomimetic side effects. Their data were dis-
carded. The 12 participating subjects (sixmen, six women) had
amean age of 24 (range 20e31) yr, weight of 68 (52e102) kg and
body mass index of 22 (19e30) kg m2. All 12 subjects
completed the study without major side effects.Side effects
Side effects included nausea (occurred on seven occasions),
headache (two occasions) and anxiety (one occasion). Mean
drug high VRS scores (SD) were: remifentanil/esketamine 7.2
(1.9), remifentanil/placebo 1.9 (2.3; P<0.001 vs remifentanil/
esketamine) and esketamine (visit 3) 6.9 (2.5; P¼0.75 vs remi-
fentanil/esketamine). Sedation VRS scores were remifentanil/
esketamine 7.0 (2.5), remifentanil/placebo 3.7 (2.4; P<0.001 vs
remifentanil/esketamine) and esketamine (visit 3) 6.3 (2.6;
P¼0.18 vs remifentanil/esketamine).Effect of esketamine vs placebo on remifentanil-
induced respiratory depression
The average esketamine concentrations are given in Figure 1A;
mean (SD) peak plasma esketamine concentration was 381 (65)
ng ml1. The end-tidal PCO2 values were similar between
treatments: mean end-tidal PCO2 esketamine 6.6 (0.4) kPa vsplacebo 6.5 (0.5) kPa (P¼0.20). The target remifentanil con-
centration was somewhat higher in the esketamine arm [1.0
(0.4) ng ml1] compared with the placebo arm [0.90 (0.3) ng
ml1, P¼0.01].
Figure 1B and C demonstrate that esketamine but not pla-
cebo antagonised remifentanil-induced respiratory depres-
sion. Remifentanil had similar effects in the two arms of the
study with a reduction from 19.9 (0.4) to 12.2 (2.3) litre min1 in
the esketamine arm and from 20.1 (0.9) to 12.2 (1.3) litre min1
in the placebo arm of the study. Adding placebo had no effect
on remifentanil-induced respiratory depression [change in
ventilation from 12.2 (1.3) to 12.3 (2.2) litre min1]. In contrast,
esketamine increased ventilation from 12.2 (2.3) to 16.6 (4.1)
litre min1 (an increase of 35%; paired t-test: P<0.01 vs
placebo).
In both treatment arms, remifentanil affected both venti-
latory frequency and tidal volume (Supplementary Fig. S2). In
the remifentanil/esketamine and remifentanil/placebo arms,
remifentanil reduced ventilatory frequency from 17.1 (3.7) to
14.7 (3.1) bpm (P<0.01) and 17.5 (2.9) to 14.9 (2.5) bpm (P<0.01),
respectively, and tidal volume from 1220 (283) to 853 (955) ml
(P<0.01) and 1150 (222) to 812 (113) ml (P<0.01), respectively.
Esketamine had a selective effect on ventilatory frequency
with an increase from 14.7 (3.1) to 18.6 (3.9) (P<0.01). Tidal
volume showed a small albeit insignificant increase 853 (156)
to 955 (396) ml by esketamine. Placebo had no effect on either
ventilatory frequency or tidal volume.PKePD analysis
The PK parameter estimates are given in Supplementary
Table S1. The parameter estimates of the final three-
compartment model were similar to that of Sigtermans and
colleagues,19 with the exception of the clearances that were 83
(2)% of the earlier estimates. Goodness of fit plots are given in
Figure 2AeC, showing measured vs individually predicted
esketamine concentrations (Fig. 2A), conditional weighted re-
siduals with heε interaction (CWRESI) vs time (Fig. 2B) and the
NPD (Fig. 2C). All indicate that the model adequately described
the data.
The best PD model (Table 1 and Supplementary Table S2) is
a mixture model with remifentanil effect on Y1 and Y2, an
esketamine effect on CKD2 (i.e. Y2) and Q fixed to 1. The PD
parameter estimates of the best model are given in Table 1.
Examples of data fits are given in Figure 3 for an esketamine
responder (Fig. 3A, median fit with R2¼0.719), an esketamine
non-responder (Fig. 3b), a placebo responder (Fig. 3C) and a
placebo non-responder (Fig. 3D, best fit with R2¼0.952). Good-
ness of fit plots are given in Fig. 3DeF. Inspection of the indi-
vidual fits and the goodness of fit plots indicate that the model
adequately described the data.Remifentanil effect
The model has two ventilation components [Y1 and Y2,
equations (2) and (3)] at which remifentanil acted. The effect of
remifentanil was 39% at Y2 and 61% at Y1 [compare parameter
l of equation (4) and Table 1]. Remifentanil acted on the two
ventilation components with different potencies and dy-
namics. Y1 is affected more slowly [t½R1¼12.2 (2.6) min] with
relatively low potency [C501¼1.24 (0.15) ng ml1] and high G1
[8.44 (0.64)] than the remifentanil effect at Y2 [t½R2¼2.15 (0.49)
min, C502¼0.46 (0.06) ng ml1 and G2¼4.44 (0.64)]. The exis-
tence of the two components is well illustrated in Fig. 3D, a
Table 1 Pharmacodynamic parameter estimates. _VBLNis baseline ventilation, C501 is the remifentanil concentration causing a 50%
decline of VBLN, C502 is the remifentanil concentration causing a 50% decline the ventilatory CO2 sensitivity, t½R1 and t½R2 are the
blood-effect-site equilibration half-times linked to components Y1 and Y2, respectively [equations (1) and (2)], G1 and G2 are shape
factors of components Y1 and Y2, respectively [equations (1) and (2)], l is a constant, CKD1 and C
K
D2 are the esketamine concentration
causing a doubling of remifentanil potency parameters C501 and C502, respectively, Q a shape parameter [equations (3) and (4)], P the
responder rate and s2a the additive residual error. SEE, standard error of estimate
Estimate SEE u2 SEE n2 SEE
Remifentanil effect on ventilation
_VBLN (litre min
1) 20.1 0.26 e e 0.006 0.002
l 0.39 0.01 e e
C501 (ng ml
1) 1.24 0.15 0.14 0.07
C502 (ng ml
1) 0.46 0.06 0.14 0.08
t½R1 (min) 12.2 2.6 0.26 0.12
t½R2 (min) 2.15 0.49 0.49 0.37
G1 8.44 0.64 0.24 0.08
G2 4.37 0.64 0.24 0.08
Esketamine effect on remifentanil-induced respiratory depression
CKD1(ng ml
1) e e e e
CKD2 (ng ml
1) 127 33.9 0.37 0.17
Q 1 (FIX) e 0.72 0.36
P(Responder to esketamine) 0.83 0.12
P(Responder to placebo) 0.23 0.15
s2a 2.39 0.54
Fig 2. Goodness of fit plots of the pharmacokinetic (AeC) and the pharmacodynamic models (DeF). Panels (A,D) are the measured vs the
individual predicted esketamine concentration and ventilation, respectively; (B,E) are the conditional weighted residuals with heε
interaction (CWRESI) vs time for esketamine concentration and ventilation, respectively; and (C,F) the normalised prediction discrepancy
for esketamine concentration and ventilation, respectively. In (B,E) the red line is a smoothing curve; in (B,C,E,F) the orange lines are the
median (solid line) with 95% confidence intervals (CI) (broken lines). NPD, normalised prediction discrepancies.
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Fig 3. Pharmacokinetic and pharmacodynamic data fits of an esketamine responder (A; median fit), an esketamine non-responder (B), a
placebo responder (C) and a placebo non-responder (D; best fit). The data show the esketamine concentration (green dots), pharmaco-
kinetic data fits (green lines), the measured ventilation (blue dots), the pharmacodynamic data fits (continuous red lines), the effect of
remifentanil without the presence of ketamine or placebo (A,C, red broken lines), ketamine or placebo infusion schemes [green surfaces in
(A,B), yellow surfaces in (C,D)] and the target remifentanil concentration (black lines).
Esketamine counters opioid respiratory depression - 1123placebo experiment, where an initial rapid decrease in venti-
lation is followed by a slow further decline. The absence of an
Y1 component in some subjects is explained by the fact that
the slow component was only present when target remi-
fentanil concentrationswere relatively high and occurredwith
a steep concentrationeresponse relationship. This reflected by
the relatively high values of parameter estimates C501 and G1.Esketamine and placebo effects
Esketamine had an exclusive effect on component Y2 and
doubled C502 at a concentration of 127 (34) ng ml
1 ðCKD2Þ; an
effect on C501 was not identifiable. Esketamine blood-effect-
site equilibration half-time (t½E) was not significantly
different from 0, indicative that the esketamine effect was
driven by plasma PK. In some subjects, a response to placebo
treatment was observed (see Fig. 3C for an example). To
quantify the placebo effect, it was assumed that esketamine
was present and had an effect of C502. This led to a placebopotency parameter CKD2ðplaceboÞwith value 363 (37.5) ng ml1,
a factor of 3 smaller than the esketamine CKD2: Probability of
being a responder to esketamine or placebo was 83 (12)% and
23 (15)%, respectively, which corresponds to 10 responders to
esketamine and three to placebo.Doseeresponse relationship
To get an indication of the steady-state doseeresponse re-
lationships, the two inputs to the PDmodel are plotted against
ventilation in Figure 4. Figure 4A gives the target remifentanil
concentrationeventilation relationship at several esketamine
concentrations (ranging from 0 to 400 ng ml1); Figure 4B gives
the esketamine concentrationeventilation relationship at a
number of target remifentanil concentrations (ranging from
0 to 2 ng ml1). In both Figure 4A and B, the maximum
observed concentrations are depicted by the grey broken lines.
All values beyond these lines are extrapolations. Figure 4C
combines the data from Figure 4A and B and gives the
Fig 4. (A) Steady-state relationship of target remifentanil concentration vs ventilation at increasing esketamine steady-state concentrations
(0e400 ng ml1). The grey broken line reflects the mean target remifentanil concentration applied in the study. The effect of target
remifentanil concentrations > 1 ng ml1 on ventilation are extrapolations. (B) Steady-state relationship of esketamine concentration vs
ventilation at increasing target remifentanil concentrations (0e2 ng ml1). The grey broken line reflects the peak esketamine concentration
observed in the study. The effect of esketamine concentrations > 400 ng ml1 on ventilation are extrapolations. (C) Response surface of the
interactive effect of steady-state esketamine concentration (y-axis), target remifentanil concentration (x-axis) vs ventilation (z-axis).
1124 - Jonkman et al.response surface of esketamine concentration (y-axis), target
remifentanil concentration (x-axis) against ventilation
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Effect of esketamine on poikilocapnic ventilation
Esketamine plasma concentrations of the observational study
were similar to those observed in the randomised trial
(Fig. 1A), with peak plasma concentrations of 378 (24) ng ml1.
Esketamine induced a small decrease in end-tidal PCO2 of 0.4
kPa from 5.2 (0.3) kPa (baseline) to 4.8 (0.4) kPa (last minute of
esketamine infusion; paired t-test: P<0.01) but had no effect on
ventilation [ _VBLNchanged from 8.9 (0.6) litre min
1 (baseline) to
9.4 (1.6) litre min1 (last minute of esketamine infusion),
P¼0.12]. Changes in ventilation and end-tidal PCO2 were
restricted to the final minute of the highest esketamine infu-
sion (Fig. 1D).Discussion
The main findings from our study are that esketamine dose-
dependently reverses remifentanil-induced respiratory
depression, while it has a little or no effect when ventilation is
not depressed by the opioid.
PD model
Remifentanil effect
We constructed a PD model in which both remifentanil and
esketamine could affect breathing via actions at component
Y1, component Y2 [equations (2e4)], or both. We observed that
remifentanil reduced ventilation via an effect at both parts, at
Y1 with relatively low potency and slow dynamics, and at Y2
with relatively high potency and faster dynamics (Table 1). The
initial rapid decrease in ventilation after the start of remi-
fentanil infusion is a result of its effect on Y2, while the slow
decrease in ventilation thatwas observed in some subjectswas
a result of an effect at Y1. In mammals, ventilatory control has
CO2-sensitive and CO2-insensitive components as described inequation (1), where _VBLN is the CO2-insensitive and S the CO2-
sensitive component.18,23,24 In our analysis, we link a drug ef-
fect at Y1 to an action at CO2-insensitive ventilation, while an
effect at Y2 is linked to the CO2-sensitive operator of ventila-
tion. These associations seem hypothetical but are plausible
when we take the results of visit 3 into account where esket-
amine had little effect on resting ventilation (i.e. Y1 or _VBLN);
see also the following section (Esketamine effect).
We did not directly estimate the value of S in our analysis.
However, parameter l is an indirect estimate of S. Since
lY2¼S(PTCO2ePTBCO2) z 8 litre min1, the value of S is esti-
mated to be approximately 8 litre min1 kPa1 (assuming that
PTCO2ePTBCO2z1 kPa),
24 which is within the range of ventila-
tory CO2 sensitivities observed in healthy young volunteers.
24
The reason for a difference in remifentanil potency and dy-
namics at components Y1 and Y2 remains unknown but could
be related to the opioid effect on central neuronal dynamics,
causing a slow reduction of CO2-insensitive ventilation.
25
Previously we tested the effect of remifentanil on ventila-
tion in open loop conditions.26 The remifentanil effect in that
study was modelled with just one component with values for
C50 (1.6 ng ml
1) and t½R (0.53 min) in the same range as in the
current study for Y2. We relate the inability to detect a slow
component (Y1) to the short infusion times (0.5e6 min) and
open loop (i.e. poikilocapnic) conditions in that study. With
respect to the latter condition, any slow reduction in ventila-
tion might have been counteracted by the slow increase in
arterial CO2. Apparently, the open-loop PD model was unable
to detect such a slow effect, if at all it occurred in these short
infusion experiments.Esketamine effect
Esketamine (at a cumulative dose of 40 mg) exclusively
impacted on Y2.We argue that (low-dose) esketamine interacts
with the ventilatory control system under conditions that the
central respiratory network is affected by an opioid (i.e. under
conditions of hypoventilation). We come to this conclusion as
the same esketamine dose had only a limited effect under
Esketamine counters opioid respiratory depression - 1125baseline conditions (i.e. without the presence of an opioid; visit
3). Consequently, as remifentanil and other opioids reduce
ventilatory CO2 sensitivity,
20,27e29 our data suggest that esket-
amine increased CO2 chemosensitivity (i.e. parameter S) after
its reduction by remifentanil. Also, other respiratory stimu-
lants acting within the respiratory network, such as the
ampakines, stimulate breathing exclusively under conditions
of hypoventilation by increasing the (reduced) ventilatory CO2
sensitivity.29,30 Still, we cannot exclude some albeit small
esketamine effect at _VBLN as the data from visit 3 still indicate
some effect on ventilation, which might have been under-
estimated a result of the open loop conditions of visit 3.Esketamine- and racemic ketamine-induced
stimulation vs depression of breathing
While some experimental work in both animals and humans
shows racemic ketamine-induced respiratory stimulation in
agreement with our observations,12e15 others show an inhib-
itory effect of ketamine on ventilation.31e35 For example,
Bourke and colleagues31 studied the interaction of racemic
ketamine and morphine in six male volunteers. Using an
experimental design very similar to this study, they showed a
dose-dependent reduction of isohypercapnic (end-tidal PCO2
6.6 kPa) ventilation by ketamine (cumulative dose increased
from 0.39 to 3.0 mg kg1) and morphine (0.2 and 0.4 mg kg1);
the combination of ketamine and morphine had an additive
negative effect on breathing.31 Using CO2-rebreathing, Hamza
and colleagues35 showed a 40% reduction of the slope of the
_VE  CO2 response by an anaesthetic dose of racemic keta-
mine (2 mg kg1 followed by 0.04 mg kg1 min1) in a paedi-
atric population (age 6e10 yr). We previously observed in mice
that esketamine produced a dose-dependent reduction of the
_VE  CO2 response slope in a dose range of 10e200 mg kg1,
with frequent inspiratory pauses in the higher dose range.32
Differences in species, dose, ketamine formulation or experi-
mental set-up can only explain part of the differences in study
outcomes. For example, our cumulative esketamine dose of
0.57 mg kg1 esketamine falls well within the dose range
studied by Bourke and colleagues,31 even when taking into
account a possible potency difference between racemic keta-
mine and the S(þ)-isomer.36 Possibly, ketamine’s metabolites
are involved in the respiratory effects of the parent drug (see
item (iii) in paragraph “Mechanism of esketamine-induced
respiratory depression”). If so, then differences in PK among
species and between isomers may explain some of the
observed differences. It is important to realise that we and
others observed a ketamine-induced stimulatory effects on
breathing at subanaesthetic ketamine doses.13,15 In rats,
Eikermann and colleagues14 showed that respiratory stimu-
lation persists even at anaesthetic doses, while Hamza and
colleagues35 found the reverse in children. Further human
studies are needed to fully understand the complex behaviour
of the low- and high-dose ketamine isomers on breathing.
An interesting observation is that, in contrast to remi-
fentanil, which reduced both tidal volume and ventilatory
frequency, esketamine selectively increased ventilatory fre-
quency (Supplementary Fig. S2). It has recently been proposed
that tidal volume is regulated by metabolic stimuli, while
respiratory frequency is driven by fast non-metabolic fac-
tors.37,38 Our findings then suggest that remifentanil has a
metabolic effect, while the esketamine effect was related to
non-metabolic stimuli (e.g. stress, behavioural stimuli, or
both). This seems to disagree with the findings of this studythat esketamine increased ventilatory CO2 sensitivity, which
is a component of metabolic control.38 Additionally, the pro-
posed mechanisms of esketamine-induced respiratory stim-
ulation all seem metabolic in nature (see below). Possibly,
behavioural effects of isohypercapnia may have affected the
study outcome. However, all subjects who completed the
study were highly comfortable during all three visits. Further
studies are needed to address the mechanistic pathway of
esketamine within the ventilatory control system.
Extrapolation of our results to higher remifentanil con-
centrations suggests that even in case of the complete cessa-
tion of breathing (i.e. opioid-induced apnoea), low-dose
ketamine may restore breathing activity (Fig. 4). Further
studies are needed to verify the validity of our model at deep
levels of respiratory depression (e.g. at remifentanil plasma
concentrations >1.25 ng ml1). If corroborated, ketamine be-
haves similarly to CX717, an ampakine that restores respira-
tory activity following fentanyl-induced apnea.10 However,
ketamine does not appear to act like drugs that exert their
effect at the carotid bodies or drugs with reduced efficacy at
deeper levels of opioid-induced respiratory depression (i.e.
ceiling behavior).39Mechanism of esketamine-induced respiratory
stimulation
Although our study was not specifically designed to unearth
the mechanism of the stimulatory effect of esketamine on
breathing, it is relevant to discuss possible mechanisms. (i)
Esketamine produces a strong increase in sympathetic outflow
and reduces the reuptake of neuronal norepinephrine.19
Monoaminergic neurotransmitters play an important role in
ventilatory control.40 Increased synaptic concentrations of
noradrenaline stimulate breathing activity and increase
ventilatory CO2 reactivity.
41,42 (ii) Esketamine may stimulate
breathing though N-methyl-D-aspartate receptor blockade.
Some indirect evidence comes from an animal model of the
Rett syndrome.43 Patients with Rett syndrome have mental
retardation and experience severe breathing irregularities
because to mutations in the MECP2 gene. In a mouse model of
Rett syndrome, ketamine reduced the number of apnoeic
events by actively stimulation of breathing activity. (iii)
Finally, it may well be that the esketamine metabolite
hydroxynorketamine contributed to the respiratory effects of
the parent drug. Hydroxynorketamine is an agonist at the
AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid) receptor.44 AMPA receptors are expressed in the brain-
stem respiratory network, for example within the pre-
B€otzinger complex, an area of the brain involved in respiratory
rhythmogenesis, and play an important role in the mainte-
nance of respiratory drive.45,46 Of interest is the observation
that so called ampakines, drugs that act selectively at the
AMPA receptors, increase the respiratory drive in both animal
and human studies, but, as stated earlier, only under condi-
tions of hypoventilation.29,30 For example, the ampakine
CX717 counters alfentanil-induced respiratory depression to a
50% depression of _VE  CO2 sensitivity.29 An effect of esket-
amine via hydroxynorketamine at AMPA receptors may
explain the absence of response in some subjects who are poor
metabolisers. This remains speculative at present, as we did
not measure hydroxynorketamine plasma concentrations in
our subjects. Future studies will need to resolve whether
hydroxynorketamine plays an important role in the respira-
tory effects of ketamine. If so, this would mirror the
1126 - Jonkman et al.observation in rodents that hydroxynorketamine rather than
ketamine plays a major role in the generation of its antide-
pressant effects.44
In summary, we observed that remifentanil depressed
ventilation in healthy volunteers by reducing ventilatory CO2
sensitivity, an effect that was partially countered by esket-
amine. These findings could indicate that the use of low-dose
esketamine in postoperative patients may not only reduce
opioid consumption but will also stabilise breathing and
consequently reduce the probability of fatal events. The
esketamine dose needed for such an effect is between 12 and
24 mg h1 (for a 70 kg patient). However, the observed ad-
vantageous effects of esketamine should be balanced against
its side effect profile, most importantly the psychedelic
symptoms that may be perceived by some patients as
extremely frightful. We believe that additional studies are still
needed and we plan to construct esketamine utility functions
to determine the optimal esketamine dose that produces res-
piratory stimulation with minimal side effects.47,48Authors’ contributions
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